<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206595</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402-C-203</org_study_id>
    <nct_id>NCT01206595</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sustained Release Encapsulated Bupivacaine (SKY0402) Administered as a Nerve Block in the Management of Postoperative Pain in Subjects Undergoing Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine the appropriate dose of SKY0402
      administered as a nerve block for the management of postoperative pain following
      bunionectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2, multicenter, randomized, double blind, dose escalating/de-escalating study
      evaluated the safety, efficacy, and pharmacokinetics of a single dose of SKY0402 compared to
      a single 125 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects
      undergoing bunionectomy.

      Up to 88 subjects were to be randomized in five consecutive cohorts. The dose of bupivacaine
      HCl (125 mg) was to remain constant for all cohorts. After completion of Cohort 1, the
      decision to increase or decrease the dose of SKY0402 was made by a Cohort Data Review
      Committee following a review of pharmacokinetic, safety, and selected efficacy data from the
      previous cohort.

      Study drug was to be administered as an ankle block, with or without a tourniquet, between 1
      hour before the induction of general anesthesia and 20 minutes before the end of general
      anesthesia. The ankle block procedure consisted of five injections via three skin entries
      targeting the following nerves: posterior tibial, sural, deep peroneal, superficial peroneal,
      and saphenous.

      The use of intravenous fentanyl during general anesthesia was permitted, but was not to
      exceed 250 micrograms. The intraoperative use of morphine was prohibited. Postoperatively,
      subjects had access to both opioid and non-opioid supplemental pain medication under general
      guidelines. Blood samples for the determination of plasma bupivacaine concentrations were
      obtained at Baseline and at specified time points through 96 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain</measure>
    <time_frame>Through 96 hours postdose</time_frame>
    <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Through 30 days postdose</time_frame>
    <description>All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>SKY0402</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose, low-mid dose, and mid-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>Single dose of SKY0402 administered as a nerve block</description>
    <arm_group_label>SKY0402</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Single dose of 125 mg administered as a nerve block</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects were eligible for enrollment if they met the following criteria:

          1. Males and females â‰¥18 years of age at the Screening Visit. NOTE: Eligible females were
             postmenopausal or surgically sterile, or, if of child bearing potential, were not
             pregnant or nursing, and they agreed to not become pregnant during the study by using
             acceptable means of contraception for at least 1 month before and 1 month after
             dosing, including any of the following: hormonal contraceptives (oral, injectable,
             implantable), effective barrier methods (e.g., condoms with spermicide), intrauterine
             device (IUD), lifestyle with a personal choice of abstinence, non-heterosexual
             lifestyle, or in a strictly monogamous relationship with a partner who has had a
             vasectomy.

          2. Scheduled to undergo a primary unilateral first metatarsal bunionectomy repair under
             general anesthesia, with or without internal fixation.

             NOTE: For the purpose of this protocol, all surgical procedures involving osteotomy of
             the first metatarsal (significant bone resection, excision, surgical fracture, etc.)
             or fusion of the first metatarsal phalangeal joint were considered qualified
             procedures, whether or not performed specifically to repair a bunion (hallus valgus
             deformity). Surgical techniques accompanied by minimal bone excision (e.g.
             cheilectomy) or procedures limited to soft tissue repair were not eligible for this
             study.

          3. American Society of Anesthesiology (ASA) Physical Class 1 or 2.

          4. Able and willing to comply with all study visits and procedures.

          5. Capable of speaking and understanding the local language sufficiently to provide
             responses to pain assessment scales.

          6. Willing and capable of providing written informed consent.

        Exclusion Criteria:

        Subjects were excluded from the study if they met any of the following criteria:

          1. Clinically significant electrocardiogram (ECG) abnormalities at Screening or on Day 1
             (before dosing).

          2. Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.

          3. Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the Investigator, might have increased the risk of surgery or
             complicated the subject's postoperative course.

          4. Opioid medication usage during the 7 day period preceding the administration of study
             drug.

          5. Current medical conditions that could have required treatment with analgesic
             medications in the postoperative period for pain that was not surgically related
             (e.g., rheumatoid arthritis).

          6. Body mass index &gt;30 mg/kg2.

          7. Body weight less than 60 kilograms.

          8. History of hypersensitivity or idiosyncratic reaction to amide type local anesthetic
             agents.

          9. History of hypersensitivity, idiosyncratic reactions, and other contraindications to
             the pain control agents (opioid or non-opioid) anticipated to be used postoperatively.
             These contraindications may have included the following: angioedema and bronchospastic
             reactivity to non-steroidal anti-inflammatory drug (NSAID), peptic ulcer (active
             within the last 3 months), or hepatic or renal insufficiency.

         10. Coagulation disorders or ongoing anticoagulation treatment.

         11. Administration of an investigational drug within 30 days or 5 half lives (of
             elimination), whichever was longer, prior to study drug administration.

         12. Suspected or known history of substance abuse and/or alcoholism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Warnott, RN, ACNP</last_name>
    <role>Study Director</role>
    <affiliation>Parica Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <results_first_submitted>November 30, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2012</results_first_posted>
  <disposition_first_submitted>September 22, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 22, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2010</disposition_first_posted>
  <last_update_submitted>April 15, 2012</last_update_submitted>
  <last_update_submitted_qc>April 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative Pain</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SKY0402</title>
          <description>Low-dose, low-mid dose, and mid-dose</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine HCl</title>
          <description>Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SKY0402</title>
          <description>Low-dose, low-mid dose, and mid-dose</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine HCl</title>
          <description>Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="14.04"/>
                    <measurement group_id="B2" value="55.7" spread="14.22"/>
                    <measurement group_id="B3" value="54.8" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain</title>
        <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.</description>
        <time_frame>Through 96 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine HCl</title>
            <description>A single dose of bupivacaine HCl 125 mg was administered intraoperatively by local infiltration.</description>
          </group>
          <group group_id="O2">
            <title>SKY0402 Low Dose</title>
            <description>A single dose of SKY0402 (low dose) was administered intraoperatively by local infiltration.</description>
          </group>
          <group group_id="O3">
            <title>SKY0402 Low-Mid Dose</title>
            <description>A single dose of SKY0402 (low-mid dose) was administered intraoperatively by local infiltration.</description>
          </group>
          <group group_id="O4">
            <title>SKY0402 Mid Dose</title>
            <description>A single dose of SKY0402 (mid dose) was administered intraoperatively by local infiltration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain</title>
          <description>The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical pain.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="6.1" upper_limit="11.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.3" upper_limit="9.0"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.6" upper_limit="5.4"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.3" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>All adverse events were to be recorded from the time of dosing through Day 8. Serious adverse events (SAEs) were to be recorded through Day 30.</description>
        <time_frame>Through 30 days postdose</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SKY0402</title>
          <description>Low-dose, low-mid dose, and mid-dose</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine HCl</title>
          <description>Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Immobiliaztion prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>203-837-6500</phone>
      <email>ErolOnel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

